Dosimetric comparison of intensity modulated radiotherapy and three-dimensional conformal radiotherapy in patients with gynecologic malignancies: a systematic review and meta-analysis

Baojuan Yang, Lin Zhu, Haiyan Cheng, Qi Li, Yunyan Zhang, Yashuang Zhao, Baojuan Yang, Lin Zhu, Haiyan Cheng, Qi Li, Yunyan Zhang, Yashuang Zhao

Abstract

Background: To quantitatively evaluate the safety and related-toxicities of intensity modulated radiotherapy (IMRT) dose-volume histograms (DVHs), as compared to the conventional three-dimensional conformal radiotherapy (3D-CRT), in gynecologic malignancy patients by systematic review of the related publications and meta-analysis.

Methods: Relevant articles were retrieved from the PubMed, Embase, and Cochrane Library databases up to August 2011. Two independent reviewers assessed the included studies and extracted data. Pooled average percent irradiated volumes of adjacent non-cancerous tissues were calculated and compared between IMRT and 3D-CRT for a range of common radiation doses (5-45 Gy).

Results: In total, 13 articles comprised of 222 IMRT-treated and 233 3D-CRT-treated patients were included. For rectum receiving doses ≥30 Gy, the IMRT pooled average irradiated volumes were less than those from 3D-CRT by 26.40% (30 Gy, p = 0.004), 27.00% (35 Gy, p = 0.040), 37.30% (40 Gy, p = 0.006), and 39.50% (45 Gy, p = 0.002). Reduction in irradiated small bowel was also observed for IMRT-delivered 40 Gy and 45 Gy (by 17.80% (p = 0.043) and 17.30% (p = 0.012), respectively), as compared with 3D-CRT. However, there were no significant differences in the IMRT and 3D-CRT pooled average percent volumes of irradiated small bowel or rectum from lower doses, or in the bladder or bone marrow from any of the doses. IMRT-treated patients did not experience more severe acute or chronic toxicities than 3D-CRT-treated patients.

Conclusions: IMRT-delivered high radiation dose produced significantly less average percent volumes of irradiated rectum and small bowel than 3D-CRT, but did not differentially affect the average percent volumes in the bladder and bone marrow.

Figures

Figure 1
Figure 1
Flow chart of identification and selection of papers for study.
Figure 2
Figure 2
Funnel plots for pooled average percent irradiated volume.A. Small bowel at 45Gy with IMRT. B. Small bowel at 45Gy with 3D-CRT. C. Rectum at 30Gy with IMRT. D. Rectum at 30Gy with 3D-CRT.

References

    1. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, Clarke-Pearson DL, Insalaco S. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340:1144–1153. doi: 10.1056/NEJM199904153401502.
    1. Creutzberg CL, van Putten WL, Koper PC, Lybeert ML, Jobsen JJ, Warlam-Rodenhuis CC, De Winter KA, Lutgens LC, van den Bergh AC, van de Steen-Banasik E, Beerman H, van Lent M. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet. 2000;355:1404–1411. doi: 10.1016/S0140-6736(00)02139-5.
    1. Papp Z, Csapo Z, Mayer A, Hupuczi P. [Wertheim-operation: 5-year survival of 501 consecutive patients with cervical cancer] Orv Hetil. 2006;147:537–545.
    1. Yeoh E. Radiotherapy: long-term effects on gastrointestinal function. Curr Opin Support Palliat Care. 2008;2:40–44. doi: 10.1097/SPC.0b013e3282f4451f.
    1. Vargas C, Martinez A, Kestin LL, Yan D, Grills I, Brabbins DS, Lockman DM, Liang J, Gustafson GS, Chen PY, Vicini FA, Wong JW. Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy. Int J Radiat Oncol Biol Phys. 2005;62:1297–1308. doi: 10.1016/j.ijrobp.2004.12.052.
    1. Gerstner N, Wachter S, Knocke TH, Fellner C, Wambersie A, Potter R. The benefit of Beam's eye view based 3D treatment planning for cervical cancer. Radiother Oncol. 1999;51:71–78. doi: 10.1016/S0167-8140(99)00038-9.
    1. Barillot I. [Cervix carcinomas: place of intensity-modulated radiotherapy] Cancer Radiother. 2009;13:507–510. doi: 10.1016/j.canrad.2009.05.015.
    1. Purdy JA. Intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys. 1996;35:845–846. doi: 10.1016/0360-3016(96)00223-4.
    1. Saw CB, Ayyangar KM, Enke CA. MIMiC-based IMRT- part I. Med Dosim. 2001;26:1.
    1. Saw CB, Ayyangar KM, Enke CA. MLC-based IMRT-Part II. Med Dosim. 2001;26:111–112. doi: 10.1016/S0958-3947(01)00065-6.
    1. Bucci MK, Bevan A, Roach M 3rd. Advances in radiation therapy: conventional to 3D, to IMRT, to 4D, and beyond. CA Cancer J Clin. 2005;55:117–134. doi: 10.3322/canjclin.55.2.117.
    1. Miles EA, Clark CH, Urbano MT, Bidmead M, Dearnaley DP, Harrington KJ, A'Hern R, Nutting CM. The impact of introducing intensity modulated radiotherapy into routine clinical practice. Radiother Oncol. 2005;77:241–246. doi: 10.1016/j.radonc.2005.10.011.
    1. Woo SY, Sanders M, Grant W, Butler EB. Does the "peacock" have anything to do with radiotherapy? Int J Radiat Oncol Biol Phys. 1994;29:213–214. doi: 10.1016/0360-3016(94)90250-X.
    1. Whitton A, Warde P, Sharpe M, Oliver TK, Bak K, Leszczynski K, Etheridge S, Fleming K, Gutierrez E, Favell L, Green E. Organisational standards for the delivery of intensity-modulated radiation therapy in Ontario. Clin Oncol (R Coll Radiol) 2009;21:192–203. doi: 10.1016/j.clon.2008.10.005.
    1. Nutting CM, Convery DJ, Cosgrove VP, Rowbottom C, Padhani AR, Webb S, Dearnaley DP. Reduction of small and large bowel irradiation using an optimized intensity-modulated pelvic radiotherapy technique in patients with prostate cancer. Int J Radiat Oncol Biol Phys. 2000;48:649–656. doi: 10.1016/S0360-3016(00)00653-2.
    1. Intensity-modulated radiotherapy. current status and issues of interest. Int J Radiat Oncol Biol Phys. 2001;51:880–914.
    1. Portelance L, Chao KS, Grigsby PW, Bennet H, Low D. Intensity-modulated radiation therapy (IMRT) reduces small bowel, rectum, and bladder doses in patients with cervical cancer receiving pelvic and para-aortic irradiation. Int J Radiat Oncol Biol Phys. 2001;51:261–266.
    1. Georg P, Georg D, Hillbrand M, Kirisits C, Potter R. Factors influencing bowel sparing in intensity modulated whole pelvic radiotherapy for gynaecological malignancies. Radiother Oncol. 2006;80:19–26. doi: 10.1016/j.radonc.2006.04.014.
    1. Esik O, Bortfeld T, Bendl R, Nemeth G, Schlegel W. Inverse radiotherapy planning for a concave-convex PTV in cervical and upper mediastinal regions. Simulation of radiotherapy using an Alderson-RANDO phantom. Planning target volume. Strahlenther Onkol. 1997;173:193–200. doi: 10.1007/BF03039288.
    1. Meeks SL, Buatti JM, Bova FJ, Friedman WA, Mendenhall WM, Zlotecki RA. Potential clinical efficacy of intensity-modulated conformal therapy. Int J Radiat Oncol Biol Phys. 1998;40:483–495. doi: 10.1016/S0360-3016(97)00819-5.
    1. Hong L, Hunt M, Chui C, Spirou S, Forster K, Lee H, Yahalom J, Kutcher GJ, McCormick B. Intensity-modulated tangential beam irradiation of the intact breast. Int J Radiat Oncol Biol Phys. 1999;44:1155–1164. doi: 10.1016/S0360-3016(99)00132-7.
    1. Saarilahti K, Kouri M, Collan J, Hamalainen T, Atula T, Joensuu H, Tenhunen M. Intensity modulated radiotherapy for head and neck cancer: evidence for preserved salivary gland function. Radiother Oncol. 2005;74:251–258. doi: 10.1016/j.radonc.2004.11.004.
    1. Vora SA, Wong WW, Schild SE, Ezzell GA, Halyard MY. Analysis of biochemical control and prognostic factors in patients treated with either low-dose three-dimensional conformal radiation therapy or high-dose intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2007;68:1053–1058. doi: 10.1016/j.ijrobp.2007.01.043.
    1. Sirak I, Kasaova L, Petera J, Vosmik M, Zoul Z. Intensity modulated radiation therapy technique in the treatment of gynecologic malignancies. Ceska Gynekol. 2010;75:177–181.
    1. Mundt AJ, Lujan AE, Rotmensch J, Waggoner SE, Yamada SD, Fleming G, Roeske JC. Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys. 2002;52:1330–1337. doi: 10.1016/S0360-3016(01)02785-7.
    1. Heron DE, Gerszten K, Selvaraj RN, King GC, Sonnik D, Gallion H, Comerci J, Edwards RP, Wu A, Andrade RS, Kalnicki S. Conventional 3D conformal versus intensity-modulated radiotherapy for the adjuvant treatment of gynecologic malignancies: a comparative dosimetric study of dose-volume histograms small star, filled. Gynecol Oncol. 2003;91:39–45. doi: 10.1016/S0090-8258(03)00461-X.
    1. Ahmed RS, Kim RY, Duan J, Meleth S, De Los Santos JF, Fiveash JB. IMRT dose escalation for positive para-aortic lymph nodes in patients with locally advanced cervical cancer while reducing dose to bone marrow and other organs at risk. Int J Radiat Oncol Biol Phys. 2004;60:505–512. doi: 10.1016/j.ijrobp.2004.03.035.
    1. Salama JK, Roeske JC, Mehta N, Mundt AJ. Intensity-modulated radiation therapy in gynecologic malignancies. Curr Treat Options Oncol. 2004;5:97–108. doi: 10.1007/s11864-004-0042-2.
    1. D'Souza WD, Ahamad AA, Iyer RB, Salehpour MR, Jhingran A, Eifel PJ. Feasibility of dose escalation using intensity-modulated radiotherapy in posthysterectomy cervical carcinoma. Int J Radiat Oncol Biol Phys. 2005;61:1062–1070. doi: 10.1016/j.ijrobp.2004.07.721.
    1. Mell LK, Tiryaki H, Ahn KH, Mundt AJ, Roeske JC, Aydogan B. Dosimetric comparison of bone marrow-sparing intensity-modulated radiotherapy versus conventional techniques for treatment of cervical cancer. Int J Radiat Oncol Biol Phys. 2008;71:1504–1510. doi: 10.1016/j.ijrobp.2008.04.046.
    1. Igdem S, Ercan T, Alco G, Zengin F, Ozgules R, Geceer G, Okkan S, Ober A, Turkan S. Dosimetric comparison of intensity modulated pelvic radiotherapy with 3D conformal radiotherapy in patients with gynecologic malignancies. Eur J Gynaecol Oncol. 2009;30:547–551.
    1. .
    1. Koh WJ. Controversies in the radiotherapeutic management of cervical cancer. J Clin Oncol. 2003;21:218s–223s. doi: 10.1200/JCO.2003.01.224.
    1. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088–1101. doi: 10.2307/2533446.
    1. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634. doi: 10.1136/bmj.315.7109.629.
    1. Chen MF, Tseng CJ, Tseng CC, Kuo YC, Yu CY, Chen WC. Clinical outcome in posthysterectomy cervical cancer patients treated with concurrent Cisplatin and intensity-modulated pelvic radiotherapy: comparison with conventional radiotherapy. Int J Radiat Oncol Biol Phys. 2007;67:1438–1444. doi: 10.1016/j.ijrobp.2006.11.005.
    1. Roeske JC, Lujan A, Rotmensch J, Waggoner SE, Yamada D, Mundt AJ. Intensity-modulated whole pelvic radiation therapy in patients with gynecologic malignancies. Int J Radiat Oncol Biol Phys. 2000;48:1613–1621. doi: 10.1016/S0360-3016(00)00771-9.
    1. Lujan AE, Mundt AJ, Yamada SD, Rotmensch J, Roeske JC. Intensity-modulated radiotherapy as a means of reducing dose to bone marrow in gynecologic patients receiving whole pelvic radiotherapy. Int J Radiat Oncol Biol Phys. 2003;57:516–521. doi: 10.1016/S0360-3016(03)00521-2.
    1. Mundt AJ, Mell LK, Roeske JC. Preliminary analysis of chronic gastrointestinal toxicity in gynecology patients treated with intensity-modulated whole pelvic radiation therapy. Int J Radiat Oncol Biol Phys. 2003;56:1354–1360. doi: 10.1016/S0360-3016(03)00325-0.
    1. Brixey CJ, Roeske JC, Lujan AE, Yamada SD, Rotmensch J, Mundt AJ. Impact of intensity-modulated radiotherapy on acute hematologic toxicity in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys. 2002;54:1388–1396. doi: 10.1016/S0360-3016(02)03801-4.
    1. Mell LK, Kochanski JD, Roeske JC, Haslam JJ, Mehta N, Yamada SD, Hurteau JA, Collins YC, Lengyel E, Mundt AJ. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. Int J Radiat Oncol Biol Phys. 2006;66:1356–1365. doi: 10.1016/j.ijrobp.2006.03.018.
    1. Beriwal S, Gan GN, Heron DE, Selvaraj RN, Kim H, Lalonde R, Kelley JL, Edwards RP. Early clinical outcome with concurrent chemotherapy and extended-field, intensity-modulated radiotherapy for cervical cancer. Int J Radiat Oncol Biol Phys. 2007;68:166–171. doi: 10.1016/j.ijrobp.2006.12.023.
    1. Hasselle MD, Rose BS, Kochanski JD, Nath SK, Bafana R, Yashar CM, Hasan Y, Roeske JC, Mundt AJ, Mell LK. Clinical outcomes of intensity-modulated pelvic radiation therapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 2011;80(5):1436–1445. doi: 10.1016/j.ijrobp.2010.04.041.
    1. Salama JK, Mundt AJ, Roeske J, Mehta N. Preliminary outcome and toxicity report of extended-field, intensity-modulated radiation therapy for gynecologic malignancies. Int J Radiat Oncol Biol Phys. 2006;65:1170–1176. doi: 10.1016/j.ijrobp.2006.02.041.
    1. Georg D, Georg P, Hillbrand M, Potter R, Mock U. Assessment of improved organ at risk sparing for advanced cervix carcinoma utilizing precision radiotherapy techniques. Strahlenther Onkol. 2008;184:586–591. doi: 10.1007/s00066-008-1872-9.
    1. Mundt AJ, Roeske JC, Lujan AE, Yamada SD, Waggoner SE, Fleming G, Rotmensch J. Initial clinical experience with intensity-modulated whole-pelvis radiation therapy in women with gynecologic malignancies. Gynecol Oncol. 2001;82:456–463. doi: 10.1006/gyno.2001.6250.
    1. Roeske JC, Bonta D, Mell LK, Lujan AE, Mundt AJ. A dosimetric analysis of acute gastrointestinal toxicity in women receiving intensity-modulated whole-pelvic radiation therapy. Radiother Oncol. 2003;69:201–207. doi: 10.1016/j.radonc.2003.05.001.
    1. Rose BS, Aydogan B, Liang Y, Yeginer M, Hasselle MD, Dandekar V, Bafana R, Yashar CM, Mundt AJ, Roeske JC, Mell LK. Normal Tissue Complication Probability Modeling of Acute Hematologic Toxicity in Cervical Cancer Patients Treated with Chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2011;79(3):800–807. doi: 10.1016/j.ijrobp.2009.11.010.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa